导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.01% | 590/4773 |
| 近一周 | -1.92% | 890/5462 |
| 近一月 | -3.09% | 1553/5421 |
| 近一季 | -2.49% | 1250/5209 |
| 近半年 | 4.43% | 826/4920 |
| 近一年 | 16.55% | 596/4366 |
| 近两年 | 74.66% | 891/2954 |
| 近三年 | 61.86% | 417/2253 |
| 成立以来 | 126.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.24% 1597/4961 |
18.53% 1367/5312 |
- - |
- - |
| 2025 | 30.97% 1272/4813 |
5.49% 774/3635 |
1.93% 2013/4076 |
21.47% 1787/4524 |
0.28% 2087/4813 |
| 2024 | 13.65% 1118/3463 |
5.30% 373/2808 |
1.11% 500/3014 |
11.72% 2474/3129 |
-4.46% 2468/3463 |
| 2023 | -9.74% 1221/2656 |
2.25% 1391/2280 |
-4.77% 1284/2385 |
-4.03% 1043/2515 |
-3.41% 680/2655 |
| 2022 | -16.52% 487/2207 |
-8.84% 297/1919 |
6.05% 781/2016 |
-12.01% 627/2113 |
-1.86% 1750/2208 |
| 2021 | 26.40% 99/1822 |
7.40% 73/1255 |
5.59% 800/1330 |
9.33% 137/1466 |
1.94% 742/1822 |
| 2020 | 39.46% 331/1250 |
-3.25% 295/1028 |
21.83% 222/1067 |
15.03% 241/1164 |
2.86% 960/1184 |
| 2019 | - - |
- - |
- - |
- - |
7.33% 452/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏扬中证500质量成长ETF联接A VS. 长安沪深300非周期A(740101) |